{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:45:08Z","timestamp":1785408308008,"version":"3.56.0"},"reference-count":50,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0HIV and AIDS continues to be a critical public health challenge, with sub-Saharan Africa shouldering the heaviest burden. Progress towards disease management has been implemented over the years, and antiretroviral therapy (ART) has been the most significant milestone. The World Health Organization recommended dolutegravir as the second line of treatment for the disease. A dolutegravir-based regimen has been appreciated for its great benefits. While its effectiveness is apparent, reports of side effects have raised concerns about adherence, posing a challenge to long-term treatment success.\nObjectives:\u00a0This study explored the perceptions of people living with HIV (PLHIV) in Limpopo province regarding the use of dolutegravir-based regimens.\nMethod:\u00a0A qualitative, explorative-descriptive design was followed. Twenty individual semi-structured interviews were conducted. Purposive sampling and sample size were determined when data saturation was reached. Thematic analysis was used.\nResults:\u00a0Four major themes emerged: high acceptance of dolutegravir, limited knowledge of treatment details, the burden of managing long-term ART and barriers to adherence, including concerns about side effects.\nConclusion:\u00a0While dolutegravir was generally well accepted, there were notable deficiencies in understanding treatment, underscoring the importance of improving patient education to ensure enhanced adherence to treatment. This study provides critical insights into the lived experiences of PLHIV using dolutegravir, offering valuable direction for future interventions aimed at improving adherence and optimising treatment outcomes in HIV care.\nContribution: The study provides context-specific insights into how PLHIV perceive and experience dolutegravir-based regimens. By uncovering both the drivers of acceptance and the hidden barriers to adherence, it offers actionable evidence to guide patient-centred ART counselling, inform policy decisions and strengthen HIV treatment programmes to achieve sustained viral suppression in similar settings.<\/jats:p>","DOI":"10.4102\/curationis.v49i1.2815","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:51:03Z","timestamp":1771483863000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Perceptions of dolutegravir-based regimen use among people living with HIV in Limpopo province: A qualitative study"],"prefix":"10.4102","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6374-3763","authenticated-orcid":false,"given":"Zandile","family":"Sibeko","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/010f1sq29","id-type":"ROR","asserted-by":"publisher"}],"name":"North-West University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-8905","authenticated-orcid":false,"given":"Boitumelo","family":"Molato","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/010f1sq29","id-type":"ROR","asserted-by":"publisher"}],"name":"North-West University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-5564","authenticated-orcid":false,"given":"Salaminah","family":"Moloko-Phiri","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/010f1sq29","id-type":"ROR","asserted-by":"publisher"}],"name":"North-West University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Abudiore, O., Amamilo, I., Campbell, J., Eigege, W., Harwell, J., Conroy, J. et al., 2023, \u2018High acceptability and viral suppression rate for first-line patients on a dolutegravir-based regimen: An early adopter study in Nigeria\u2019, PLoS One 18(5), e0284767. https:\/\/doi.org\/10.1371\/journal.pone.0284767","DOI":"10.1371\/journal.pone.0284767"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Adrawa, N., Alege, J.B. & Izudi, J., 2020, \u2018Alcohol consumption increases non-adherence to ART among people living with HIV enrolled to the community-based care model in rural northern Uganda\u2019, PLoS One 15(11), e0242801. https:\/\/doi.org\/10.1371\/journal.pone.0242801","DOI":"10.1371\/journal.pone.0242801"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ahmed, S.K., Mohammed, R.A., Nashwan, A.J., Ibrahim, R.H., Abdalla, A.Q., Ameen, B.M. et al., 2025, \u2018Using thematic analysis in qualitative research\u2019, Journal of Medicine, Surgery and Public Health 6(1), 100198. https:\/\/doi.org\/10.1016\/j.jmsp.2025.100198","DOI":"10.1016\/j.glmedi.2025.100198"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Alhassan, Y., Twimukye, A., Malaba, T., Orrell, C., Myer, L., Waitt, C. et al., 2020, \u2018Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: A qualitative study with stakeholders in South Africa and Uganda\u2019, BMC Health Services and Research 20, 705. https:\/\/doi.org\/10.1186\/s12913-020-05580-0","DOI":"10.1186\/s12913-020-05580-0"},{"key":"ref4","unstructured":"Anas, N. & Ishaq, K., 2022, \u2018Qualitative research method in social and behavioural science research\u2019, International Journal of Management, Social Sciences, Peace and Conflict Studies 5(1), 89\u201393."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bacha, J.M., Dlamini, S., Anabwani, F., Gwimile, J., Kanywa, J.B., Farirai, J. et al., 2023, \u2018Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real-world settings in six countries in Eastern and Southern Africa\u2019, The Pediatric Infectious Disease Journal 42(7), 576\u2013581. https:\/\/doi.org\/10.1097\/INF.0000000000003814","DOI":"10.1097\/INF.0000000000003878"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cahn, P., Madero, J.S., Arribas, J.R., Antinori, A., Ortiz, R., Clarke, A.E. et al., 2022, \u2018Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy\u2013naive adults with HIV-1 infection\u2019, AIDS 36(1), 39\u201348. https:\/\/doi.org\/10.1097\/QAD.0000000000003095","DOI":"10.1097\/QAD.0000000000003070"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Calmy, A., Sanchez, T.T., Kouanfack, C., Mpoudi-Etame, M., Leroy, S., Perrineau, S. et al., 2020, \u2018Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): Week 96 results from a two-group, multicentre, randomised, open-label, phase 3 non-inferiority trial in Cameroon\u2019, The Lancet HIV 7(10), e677\u2013e687. https:\/\/doi.org\/10.1016\/S2352-3018(20)30210-3","DOI":"10.1016\/S2352-3018(20)30238-1"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Cardoso, T.S., Costa, J.O., Reis, E.A., Silveira, M.R., Bonolo, P.F., Santos, S.F.D. et al., 2019, \u2018Which antiretroviral regimen is associated with higher adherence in Brazil? A comparison of single, multi, and dolutegravir-based regimens\u2019, Cadernos de Sa\u00fade P\u00fablica 35(9), e00115518. https:\/\/doi.org\/10.1590\/0102-311x00115518","DOI":"10.1590\/0102-311x00115518"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Casalini, C., D\u2019Almeida, Y., Nassam, M.A., Kokoloko, E., Wade, S., Tchupo, J.P. et al., 2023, \u2018Targeted solutions to increase dolutegravir coverage, viral load testing coverage and viral suppression among children living with HIV in Togo: An analysis of routine facility data\u2019, PLoS One 18, e0296293. https:\/\/doi.org\/10.1371\/journal.pone.0296293","DOI":"10.1371\/journal.pone.0296293"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Chanie, G.S., Belachew, E.A., Seid, A.M., Limenh, L.W., Mitku, M.L., Beyna, A.T. et al., 2025, \u2018Patients-reported neuropsychiatric adverse events and associated factors among PLHIV patients receiving DTG-based regimen antiretroviral therapy in Ethiopia: A multi-centre cross-sectional study\u2019, BMC Psychiatry 25, 383. https:\/\/doi.org\/10.1186\/s12888-025-05726-2","DOI":"10.1186\/s12888-025-06820-5"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Chapola, J.C., Lee, F., Bula, A., Rosenberg, N.E., Tseka, J., Chagomerana, M. et al., 2023, \u2018Knowledge and perceptions about dolutegravir and dolutegravir counselling: A qualitative study among women living with HIV\u2019, BMC Women\u2019s Health 23, 478. https:\/\/doi.org\/10.1186\/s12905-023-02619-8","DOI":"10.1186\/s12905-023-02630-7"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Cohn, J., Bekker, L.G., Bygrave, H. & Calmy, A., 2015, \u2018Hit me with your best shot: Dolutegravir \u2013 A space in the next WHO guidelines?\u2019, AIDS 29(17), 2067\u20132070. https:\/\/doi.org\/10.1097\/QAD.0000000000000810","DOI":"10.1097\/QAD.0000000000000813"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"De Nicol\u00f2, A., Calcagno, A., Motta, I., De Vivo, E., D\u2019Avolio, A., Di Perri, G. et al., 2022, \u2018The effect of rifampicin on darunavir, ritonavir and dolutegravir exposure within peripheral blood mononuclear cells: A dose-escalation study\u2019, Antimicrobial Agents and Chemotherapy 66(8), e00136\u201322. https:\/\/doi.org\/10.1128\/aac.00136-22","DOI":"10.1128\/aac.00136-22"},{"key":"ref14","unstructured":"DePoy, E., 2024, Introduction to research e-book: Understanding and applying multiple strategies, Elsevier Health Sciences, Orono, ME."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Enworo, O.C., 2023, \u2018Application of Guba and Lincoln\u2019s parallel criteria to assess trustworthiness of qualitative research on indigenous social protection systems\u2019, Qualitative Research Journal 23(3), 372\u2013384. https:\/\/doi.org\/10.1108\/QRJ-01-2023-0009","DOI":"10.1108\/QRJ-08-2022-0116"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Evitt, L.A., Nanji, S., Grove, R.A., Okoli, C., van Wyk, J. & Snedecor, S.J., 2023, \u2018An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1\u2019, AIDS Research and Therapy 20, 17. https:\/\/doi.org\/10.1186\/s12981-023-00507-1","DOI":"10.1186\/s12981-023-00507-1"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Eze, R.A., Sulaiman, N., Mat Daud, Z. & Babadoko, A., 2023, \u2018Association between belief in medicine and adherence to antiretroviral therapy among human immunodeficiency virus adults in Zaira, Kaduna State, Nigeria\u2019, Cureus 15(3), e36489. https:\/\/doi.org\/10.7759\/cureus.36489","DOI":"10.7759\/cureus.36489"},{"key":"ref18","unstructured":"Flanagan, J. & Beck, C.T., 2024, Polit & Beck\u2019s nursing research: Generating and assessing evidence for nursing practice, Lippincott Williams & Wilkins, Philadelphia, PA."},{"key":"ref19","unstructured":"Hanser, S., 2021, \u2018Investigating the effects of HAART on early markers of cardiovascular disease among HIV-positive patients in the Mankweng District, Limpopo Province\u2019, PhD thesis, University of Limpopo."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Henegar, C., Letang, E., Wang, R., Hicks, C., Fox, D., Jones, B. et al., 2023, \u2018A comprehensive literature review of treatment-emergent integrase resistance with dolutegravir-based regimens in real-world settings\u2019, Viruses 15(12), 2426. https:\/\/doi.org\/10.3390\/v15122426","DOI":"10.3390\/v15122426"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Hickey, M.D., Wafula, E., Ogachi, S.M., Ojwando, H., Orori, G., Adede, R.O. et al., 2023, \u2018Weight change following switch to dolutegravir for HIV treatment in rural Kenya during country roll-out\u2019, JAIDS Journal of Acquired Immune Deficiency Syndromes 93(2), 154\u2013161. https:\/\/doi.org\/10.1097\/QAI.0000000000003157","DOI":"10.1097\/QAI.0000000000003173"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Hussen Tale, A., Tegegne, A.S. & Belay, D.B., 2023, \u2018Predictors of viral load and medication adherence among HIV-positive adults under treatment at Felege-Hiwot Comprehensive Specialized Hospital, North-West Ethiopia\u2019, HIV\/AIDS (Auckland) 15, 477\u2013489. https:\/\/doi.org\/10.2147\/HIV.S416974","DOI":"10.2147\/HIV.S422980"},{"key":"ref23","unstructured":"Ifedilichukwu, N.H. & Joy, O.S., 2023, \u2018Antiviral targets and known antivirals (HAART)\u2019, in Antiviral strategies in the treatment of human and animal viral infections, IntechOpen https:\/\/doi.org\/10.5772\/intechopen.1113454."},{"key":"ref24","unstructured":"John, B., 2024, Strategies to mitigate drug therapy problems in resource-limited settings, Unpublished manuscript, viewed 11 October 2025, from https:\/\/www.researchgate.net\/publication\/385850886_Strategies_to_Mitigate_Drug_Therapy_Problems_in_Resource-Limited_Settings."},{"key":"ref25","unstructured":"Katjiuanjo, M.Z., 2023, \u2018Analysis of factors contributing to non-adherence to highly active antiretroviral therapy in selected facilities in Namibia: Development of an adherence improvement programme for health professionals\u2019, PhD thesis, University of Namibia."},{"key":"ref26","unstructured":"Kawuma, A., 2023, \u2018Pharmacometrics of dolutegravir and tenofovir: A quantitative approach to characterise drug-drug interactions, pharmacogenetics and optimise treatment\u2019, Doctoral dissertation, University of Cape Town."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Kwame, A. & Petrucka, P.M., 2020, \u2018Communication in nurse\u2013patient interaction in healthcare settings in sub-Saharan Africa: A scoping review\u2019, International Journal of Africa Nursing Sciences 12, 100198. https:\/\/doi.org\/10.1016\/j.ijans.2020.100198","DOI":"10.1016\/j.ijans.2020.100198"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Lee, C.Y., Lee, C.H., Tang, H.J., Tsai, H.C., Yang, C.H., Lin, Y.P. et al., 2023, \u2018Comparison of virological efficacy of DTG\/ABC\/3TG and B\/F\/TAF regimens and discontinuation patterns in persons living with advanced HIV in the era of rapid ART: A retrospective multicentre cohort study\u2019, Infectious Diseases and Therapy 12(3), 843\u2013861. https:\/\/doi.org\/10.1007\/s40121-022-00733-3","DOI":"10.1007\/s40121-022-00734-5"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Lockman, S., Brummel, S.S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A. et al., 2021, \u2018Efficacy and safety of dolutegravir- and tenofovir alafenamide fumarate-containing HIV antiretroviral treatment regimens started in pregnancy: A randomised controlled trial\u2019, The Lancet 397(10281), 1276\u20131286. https:\/\/doi.org\/10.1016\/S0140-6736(21)00533-7","DOI":"10.1016\/S0140-6736(21)00314-7"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Massawe, I.W., Chitete, H., Munkhondya, T., Nyasulu, P.S. & Mwansa, J., 2023, \u2018Knowledge and perceptions about dolutegravir and dolutegravir counselling: a qualitative study among women living with HIV\u2019, BMC Women\u2019s Health 23(1), 478. https:\/\/doi.org\/10.1186\/s12905-023-02630-7","DOI":"10.1186\/s12905-023-02630-7"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Mathur, P., 2023, \u2018Virology and natural history of HIV\u2019, in W.D. Hardy (ed.), Fundamentals of HIV medicine 2023 edition, ch. 16, pp. 173\u2013190, Oxford University Press, New York, NY.","DOI":"10.1093\/med\/9780197679098.003.0016"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Mayer, K.H., Nelson, L., Hightow-Weidman, L., Mimiaga, M.J., Mena, L., Reisner, S. et al., 2021, \u2018The persistent and evolving HIV epidemic in American men who have sex with men\u2019, The Lancet 397, 1116\u20131126. https:\/\/doi.org\/10.1016\/S0140-6736(21)00321-4","DOI":"10.1016\/S0140-6736(21)00321-4"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"McCluskey, S.M., Pepperrell, T., Hill, A., Venter, W.D.F., Gupta, R.K. & Siedner, M.J., 2021, \u2018Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: Implications for the TLD era\u2019, AIDS 35(suppl 2), S127\u2013S135. https:\/\/doi.org\/10.1097\/QAD.0000000000003082","DOI":"10.1097\/QAD.0000000000003082"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Muche, E.A., Kiflu, M. & Ayalew, M.B., 2020, \u2018Patient-reported central nervous system adverse events of efavirenz-based antiretroviral therapy in people living with HIV in Northwest Ethiopia\u2019, HIV\/AIDS \u2013 Research and Palliative Care 12, 601\u2013609. https:\/\/doi.org\/10.2147\/HIV.S263826","DOI":"10.2147\/HIV.S276111"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Nalugga, E.A., Laker, E., Nabaggala, M.S., Ddungu, A., Batte, C., Piloya, T. et al., 2022, \u2018Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda\u2019, BMC Nutrition 8(1), 107. https:\/\/doi.org\/10.1186\/s40795-022-00604-w","DOI":"10.1186\/s40795-022-00604-w"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Nelson, M., Winston, A., Hill, A., Mngqibisa, R., Bassa, A., Orkin, C. et al., 2021, \u2018Efficacy, safety and central nervous system effects after switch from efavirenz\/tenofovir\/emtricitabine to doravirine\/tenofovir\/lamivudine\u2019, AIDS 35(5), 759\u2013767. https:\/\/doi.org\/10.1097\/QAD.0000000000002769","DOI":"10.1097\/QAD.0000000000002804"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Ngowi, K.M., Minja, L., Boer, I.M.S.-D., Aarnoutse, R.E., Masika, L., Sprangers, M.A.G. et al., 2022, \u2018Predicting viral load suppression by self-reported adherence, pharmacy refill counts and real-time medication monitoring among people living with HIV in Tanzania\u2019, AIDS Research and Therapy 19(1), 51. https:\/\/doi.org\/10.1186\/s12981-022-00471-8","DOI":"10.1186\/s12981-022-00475-y"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Perez-Valero, I., Corona, D., Martinez, N., Lopez-Cavanillas, M., Lluis, C. & Luque, I., 2023, \u2018Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: A systematic review\u2019, Expert Review of Anti-infective Therapy 21(5), 655\u2013665. https:\/\/doi.org\/10.1080\/14787210.2023.2188058","DOI":"10.1080\/14787210.2023.2203914"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Phillips, A.N., Venter, F., Havlir, D., Pozniak, A., Kuritzkes, D., Wensing, A. et al., 2019, \u2018Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: A modelling study\u2019, Lancet HIV 6(2), e116\u2013e127. https:\/\/doi.org\/10.1016\/S2352-3018(18)30317-5","DOI":"10.1016\/S2352-3018(18)30317-5"},{"key":"ref40","unstructured":"Ramusilei, F.I., 2023, \u2018Views of professional nurses regarding the new antiretroviral therapy drug tenofovir, lamivudine and dolutegravir in selected clinics of Limpopo Province\u2019, Doctoral dissertation, University of Venda, Thohoyandou, viewed 27 November 2025, from https:\/\/univendspace.univen.ac.za\/items\/a4ce4d40-f5ab-4bdb-ae34-d75292f79346\/full."},{"key":"ref41","unstructured":"Rasi, V., 2021, \u2018Use and safety of antiretrovirals in pregnancy: Filling the gap between regulatory recommendation and clinical practice\u2019, Doctoral thesis, University College London."},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Singh, B., Guliani, A., Hanumanthu, V., Narang, T., Dogra, S., Handa, S. et al., 2023, \u2018A prospective study to estimate the incidence and pattern of adverse drug reactions to first-line antiretroviral therapy (tenofovir, efavirenz, and lamivudine)\u2019, Indian Journal of Sexually Transmitted Diseases and AIDS 44(1), 6\u201310. https:\/\/doi.org\/10.4103\/ijstd.ijstd_44_21","DOI":"10.4103\/ijstd.ijstd_44_21"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Temereanca, A. & Ruta, S., 2023, \u2018Strategies to overcome HIV drug resistance \u2013 Current and future perspectives\u2019, Frontiers in Microbiology 14, 1133407. https:\/\/doi.org\/10.3389\/fmicb.2023.1133407","DOI":"10.3389\/fmicb.2023.1133407"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Thivalapill, N., Simelane, T., Mthethwa, N., Dlamini, S., Lukhele, B., Okello, V. et al., 2021, \u2018Transition to dolutegravir is associated with an increase in the rate of body mass index change in a cohort of virally suppressed adolescents\u2019, Clinical Infectious Diseases 73(4), e580\u2013e586. https:\/\/doi.org\/10.1093\/cid\/ciaa1874","DOI":"10.1093\/cid\/ciaa1652"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Todorovi\u0107, Z., Dragovi\u0107, G. & Luki\u0107, R., 2024, \u2018Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women\u2019, Expert Opinion on Drug Metabolism & Toxicology 20(5), 419\u2013437. https:\/\/doi.org\/10.1080\/17425255.2024.2406605","DOI":"10.1080\/17425255.2024.2353762"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Wembulua, B.S., Cisse, V.M.P., Ka, D., Ngom, N.F., Mboup, A., Diao, I. et al., 2024, \u2018Changes in early HIV\/AIDS mortality rates in people initiating antiretroviral treatment between 2013 and 2023: A 10-year multicentre survival study in Senegal\u2019, Infectious Diseases Now 54(5), 104990. https:\/\/doi.org\/10.1016\/j.idnow.2024.104990","DOI":"10.1016\/j.idnow.2024.104990"},{"key":"ref47","unstructured":"WHO, 2022, Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations, World Health Organization, viewed 20 November 2023, from https:\/\/www.who.int\/publications\/i\/item\/9789240052390."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Willie, M.M., 2024, \u2018Population and target population in research methodology\u2019, Golden Ratio of Social Science and Education 4(2), 75\u201379. https:\/\/doi.org\/10.58970\/grsse.v4i2.339","DOI":"10.52970\/grsse.v4i1.405"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Zakumumpa, H., Kitutu, F.E., Ndagije, H.B., Diana, N.K., Ssanyu, J.N. & Kiguba, R., 2021, \u2018Provider perspectives on the acceptability and tolerability of dolutegravir-based antiretroviral therapy after national roll-out in Uganda: A qualitative study\u2019, BMC Infectious Diseases 1222. https:\/\/doi.org\/10.1186\/s12879-021-06830-0","DOI":"10.1186\/s12879-021-06933-8"}],"container-title":["Curationis"],"original-title":[],"link":[{"URL":"https:\/\/curationis.org.za\/index.php\/curationis\/article\/view\/2815\/4370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:51:16Z","timestamp":1771483876000},"score":1,"resource":{"primary":{"URL":"https:\/\/curationis.org.za\/index.php\/curationis\/article\/view\/2815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/curationis.v49i1.2815","relation":{},"ISSN":["0379-8577","2223-6279"],"issn-type":[{"value":"0379-8577","type":"print"},{"value":"2223-6279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"a2815"}}